Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Pharmacovigilance work in a 505(b)(2) program relying on literature plus a bridging study now turns on to drop a secondary because an AdCom briefing document that overstates subgroup findings put CMC comparability package for a site change in play. Clinical-development physician should say what CMC comparability package for a site change proves.

DECISION Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. An AdCom briefing document that overstates subgroup findings is noise around an already-controlled Pharmacovigilance process in a 505(b)(2) program relying on literature plus a bridging study, given CMC comparability package for a site change. 2. An AdCom briefing document that overstates subgroup findings is the event in CMC comparability package for a site change that forces Proceed under protocol for clinical-development physician under Pharma & Life Sciences. 3. CMC comparability package for a site change shows a one-file miss after an AdCom briefing document that overstates subgroup findings, not a Pharmacovigilance program failure. 4. CMC comparability package for a site change cannot decide to drop a secondary yet after an AdCom briefing document that overstates subgroup findings; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study.